声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 责任编辑：小浪快报 2026年1月26日，*ST立方（维权）（sz300344）触及跌停，跌停价0.92元，涨幅-9.16%，总市值7.64亿 元，流通市值7.63亿元，截止发稿，总成交额3584.85万元。 根据喜娜AI异动分析，*ST立方跌停原因可能如下，退市风险+业绩亏损+资金流出： 1、公司自身经营 困境：*ST立方连续三年财务造假，虚增营收5.92亿元，已触发重大违法强制退市条款，同时股价连续 多日低于1元，存在交易类强制退市风险。2025年业绩预计持续亏损，1 - 9月净利润-6220.90万元，同比 下降20.59%，全年预计仍为负，财务状况恶化，现金流紧张，这些都严重打击了投资者信心。 ...

Core Viewpoint - Zhuolang Intelligent (600545) is expected to report a significant net profit loss for the year 2025, primarily due to geopolitical influences and increased domestic market competition [1][3]. Trading Information Summary - On January 23, Zhuolang Intelligent closed at 2.71 yuan, up 0.37%, with a turnover rate of 1.28%, a trading volume of 228,500 shares, and a transaction value of 61.83 million yuan [1]. - The main funds experienced a net outflow of 10.69 million yuan, accounting for 17.29% of the total transaction value, while retail investors saw a net inflow of 11.35 million yuan, representing 18.36% of the total transaction value [1]. Earnings Disclosure Highlights - Zhuolang Intelligent forecasts a net profit loss for 2025 ranging from 190 million yuan to 380 million yuan, with the same range applicable for the net profit after deducting non-recurring gains and losses [1][3]. - The anticipated losses are attributed to decreased investment willingness from overseas clients, intensified competition in the domestic market, and an estimated foreign exchange loss of approximately 110 million yuan [1][3].

Core Viewpoint - Construction Machinery is expected to continue incurring losses in 2025, with a projected net profit attributable to shareholders of -2.072 billion yuan, indicating an increase in the loss margin compared to previous years [2][3]. Group 1: Financial Performance - In 2024, Construction Machinery reported a net profit of -988 million yuan and a net profit excluding non-recurring items of -1.001 billion yuan [5]. - The company anticipates that the losses in 2025 may double due to insufficient downstream demand in the domestic tower crane rental market, resulting from reduced new construction area and low project commencement rates [5]. - The asset-liability ratio of Construction Machinery reached 74.81% in 2024, an increase of approximately 9.5 percentage points compared to 2021 [9]. Group 2: Business Overview - Construction Machinery, established in 2001 and listed on the Shanghai Stock Exchange in 2004, is primarily controlled by Shaanxi Coal and Chemical Industry Group [6]. - The company's operations are divided into five main segments: leasing, engineering construction, steel structure manufacturing and installation, equipment sales, and transportation, with leasing being the core business, accounting for over 80% of revenue in the first half of 2025 [6]. - The construction machinery rental industry, where Construction Machinery operates, serves downstream sectors such as real estate, municipal engineering, transportation, and energy projects, all of which have seen declining demand recently [6]. Group 3: Capital Structure and Fundraising - In late 2023, Construction Machinery announced a plan to raise no more than 1.265 billion yuan through a private placement to Shaanxi Coal Group, aimed at improving liquidity and reducing debt [9]. - However, on December 23, 2025, the company decided to terminate the private placement due to various factors, including the macroeconomic environment and changes in the capital market [9].

Group 1 - The company forecasts a net loss attributable to shareholders of the parent company for the year 2025, estimated between -227 million and -190 million yuan [2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -210 million and -177 million yuan [2] - The previous year's net profit attributable to shareholders was -141.83 million yuan, with a total profit of -187.12 million yuan [4] Group 2 - The primary reasons for the anticipated loss include intense competition in the domestic operator bidding market for smart terminal products, rising procurement costs of raw materials, and a decrease in revenue from smart city projects compared to the previous year [6] - The company also noted an increase in management expenses and share-based payments contributing to the overall loss [6] - The performance forecast has not been audited by a registered accountant [3]

金地集团表示，2026年公司将积极把握行业发展规律与转型机遇，主动适应市场变化，深耕开发主业， 打造符合"好房子"标准的产品；坚持轻重并举，推动代建、物业服务、持有型资产经营等多元业态协同 发展；持续深化精益管理，聚力提质增效，致力于为股东创造长期价值。 金地集团本期业绩亏损的原因为公司销售规模下降导致可结转面积较上年减少，营业收入较上年下滑。 同时，公司根据市场情况动态调整经营及销售策略，加大去化力度，使得部分项目存货可变现净值低于 成本，基于谨慎性原则，计提了存货跌价准备和信用损失准备。 1月23日，金地集团（600383）发布2025年业绩预告，预计2025年公司实现归属于母公司所有者的净利 润为-111亿元到-135亿元；归属于母公司所有者的扣除非经常性损益后的净利润为-100亿元到-124亿 元。 ...

Core Viewpoint - ST Juewei, known as the "Duck Neck King," is facing its first annual loss since its listing, with projected revenue declining by 12.09% to 15.29% year-on-year, leading to a net loss of 1.6 billion to 2.2 billion yuan in 2025, compared to a profit of 2.27 billion yuan the previous year [1][2][3] Group 1: Financial Performance - The company expects revenue for 2025 to be between 5.3 billion and 5.5 billion yuan, marking a significant decline from previous years [1] - The net profit for 2025 is projected to be a loss of 1.6 billion to 2.2 billion yuan, a stark contrast to the profit of 2.27 billion yuan in 2024, marking the lowest profit since its listing in 2017 [1][2] - In the first three quarters of 2025, the company reported a net profit of 280 million yuan, indicating a substantial fourth-quarter loss of 4.4 billion to 5 billion yuan [1][2] Group 2: Operational Challenges - The company cites increased non-operating expenses and losses from equity investments as key factors contributing to its financial struggles [3] - ST Juewei's investments in various brands within the food and beverage sector have not yielded positive returns, with investment losses recorded at -94 million yuan, -116 million yuan, and -160 million yuan from 2022 to 2024 [3] - The company has shown signs of operational weakness, with revenue declining by 13.84% and net profit dropping by 34.04% in 2024 [3] Group 3: Market Dynamics - The company is experiencing a contraction in store numbers, with a peak of 15,950 stores in 2023, but a significant reduction to 10,713 stores by 2025, indicating a shift in its growth strategy [4] - Increased competition in the snack food industry is further squeezing the company's core business, with revenue from poultry products dropping from 3.444 billion yuan in the first three quarters of 2023 to 2.434 billion yuan in the same period of 2025 [4] - The company is shifting its strategic focus from deepening its core duck neck business to concentrating on the broader snack food sector and addressing specific consumer demands [4] Group 4: Regulatory Issues - In 2025, the company faced regulatory penalties for failing to recognize revenue from franchise store renovations, resulting in a fine of 4 million yuan and further damaging market confidence [6] - The company’s stock was placed under risk warning and subsequently removed from the Hang Seng A-share investable index, leading to a significant decline in market valuation [6] - As of January 23, 2026, the company's stock price was 13.07 yuan per share, down 2.17%, with a market capitalization of 7.92 billion yuan, reflecting a decline of over 22% since the beginning of 2025 [6]

南财智讯1月23日电，睿昂基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3990.69万元至-5986.03万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-4990.69万元至-6986.03万元。报告期内，公司实现归属于母公司所有者的净利润和归属于母公司所 有者的扣除非经常性损益的净利润同比出现较大幅度的下滑，主要有以下四个方面的原因：1、受体外 诊断行业竞争加剧以及本公司特殊事件的影响，2025年营业收入较上年下降约6,630.62万元至7,230.62万 元，同比减少27.36%至29.84%，营业收入下降导致毛利金额下降；2、报告期内，受医疗行业环境影 响，下游客户回款变慢，公司根据坏账政策增加计提应收账款信用减值损失；3、报告期内，（1）公司 分子诊断试剂研发中心及产业化建设项目暂停，且暂无续建计划，公司判断其存在减值迹象，对其计提 减值损失；（2）由于外部市场环境发生变化，子公司上海源奇生物本期业绩进一步下滑，公司结合未 来经营情况的判断，对该子公司的商誉计提减值损失；（3）由于外部市场环境发生变化，子公司武汉 百泰本期业绩进一步下滑，公司判断其 ...

赛意信息公告称，2025年公司预计归属于上市公司股东的净利润亏损7500万元-1.1亿元，上年同期盈利 1.39亿元；扣非后净利润亏损9652万元-1.32亿元，上年同期盈利1.10亿元。业绩下降主因市场波动、业 务布局优化、子公司亏损致计提商誉减值准备和坏账准备。不过，公司四季度经营性回款成效好，全年 经营性净现金流正向且快速增长。公司将推动新兴业务落地，提升盈利能力。 ...

Core Viewpoint - The company, Jemete, has announced an annual performance forecast indicating a projected net loss for 2025, attributed to various factors including changes in client business and international policies [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be a loss between 44 million to 64 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be a loss between 67 million to 97 million yuan [1] Group 2: Revenue and Profitability Factors - Overall revenue and gross profit are expected to decrease due to changes in client business and international policy impacts [1] - Although revenue from the company's own brand business has increased compared to the previous year, the ODM/OEM business has seen a reduction in order demand from domestic clients due to their own business changes [1] - International clients have shifted supply chains to Southeast Asia due to tariff policy changes and international political situations, leading to a decrease in orders for the company [1] Group 3: Financial Costs - Financial expenses have increased due to fluctuations in the currency market, with exchange losses rising as the company's export business is primarily settled in US dollars [1] - The decline in cash management income is attributed to lower market interest rates compared to the previous year [1] Group 4: Marketing and Promotion Expenses - Sales expenses have increased compared to the previous year, primarily due to the company's intensified efforts in expanding its own brand business [1] - The increase in marketing expenses has contributed to the growth in revenue from the company's own brand business [1]

证券之星消息，尚荣医疗发布业绩预告，预计2025年全年归属净利润亏损1.2亿元至1.7亿元。 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 1、受行业经营环境影响导致公司承接的医院工程项目减少,相应的公司医疗工程服务收入减少;2、医院 工程项目回款不及预期,本期计提的应收账款坏账准备增加;3、医疗耗材出口业务受国际形势的影响,出 口业务收入减少、成本增加导致毛利率下降;4、汇率波动导致公司确认的汇兑 ...